Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
The Oncologist|May 26, 2019
Long-Term Survival Outcomes After Liver Resection for Binodular Hepatocellular Carcinoma: A Multicenter Cohort StudyMing-Da Wang, Chao Li, Jun Li, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|December 25, 2024
Clinical features, risk factors, outcomes, and prediction model for intrahepatic and perihepatic abscess following hepatectomy for hepatocellular carcinomaShuo Zhu, Li-Hui Gu, Yang Shen, et al.
Hepatology International|February 3, 2021
Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter studyLei Liang, Bing Quan, Han Wu, et al.
Iliver|December 9, 2025
Development and validation of an individualized online calculator for early mortality risk after hepatectomy among patients with HCCSi-Yuan Wang, Yong-Kang Diao, Yu-Ze Yang, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|September 13, 2024
Preoperative frailty as a key predictor of short- and long-term outcomes among octogenarians undergoing hepatectomy for hepatocellular carcinoma: a multicenter comprehensive analysisYi-Fan Yang, Ping Zhang, Bo Wu, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 30, 2024
Incidence, risk factors, outcomes, and prediction model of surgical site infection after hepatectomy for hepatocellular carcinoma: A multicenter cohort studyYang Shen, Yi-Lin Hu, Jia-Hao Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II TrialHai-Dong Zhu, Wei-Jun Fan, Chang Zhao, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 22, 2025
Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapyKong-Ying Lin, Hong-Zhi Liu, Jian-Wei Liu, et al.
Gut|July 3, 2026
Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation studyYan-Jun Xiang, Zong-Han Liu, Jin-Kai Feng, et al.
Pageof 7